scispace - formally typeset
Y

Young-Myeong Kim

Researcher at Kangwon National University

Publications -  256
Citations -  11540

Young-Myeong Kim is an academic researcher from Kangwon National University. The author has contributed to research in topics: Nitric oxide & Apoptosis. The author has an hindex of 48, co-authored 247 publications receiving 10751 citations. Previous affiliations of Young-Myeong Kim include University of Pittsburgh & GenVec.

Papers
More filters
Journal ArticleDOI

Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms.

TL;DR: It is reported that NO prevents hepatocyte apoptosis initiated by the removal of growth factors or exposure to TNFα or anti-Fas antibody and by direct inhibition of caspase-3-like activity through proteinS-nitrosylation.
Journal ArticleDOI

Nitric Oxide Protects Cultured Rat Hepatocytes from Tumor Necrosis Factor-α-induced Apoptosis by Inducing Heat Shock Protein 70 Expression

TL;DR: It is demonstrated that NO can induce resistance to TNFα-induced hepatotoxicity, possibly through the stimulation of HSP70 expression.
Journal ArticleDOI

Nitric oxide as a bioregulator of apoptosis.

TL;DR: The antiapoptotic mechanism can be understood via expression of protective genes such as heat shock proteins, Bcl-2 as well as direct inhibition of the apoptotic caspase family proteases by S-nitrosylation of the cysteine thiol.
Journal ArticleDOI

Nitric Oxide as a Bifunctional Regulator of Apoptosis

TL;DR: The elucidation of the signaling events in apoptosis is occurring at a rapid pace and includes the identification of the key roles of cysteine proteases, caspases, Bcl-2 family members, and mitochondria.
Journal ArticleDOI

Targeting Nitric Oxide (NO) Delivery in Vivo. Design of a Liver-Selective NO Donor Prodrug That Blocks Tumor Necrosis Factor-α-Induced Apoptosis and Toxicity in the Liver

TL;DR: In vivo, V-PYRRO/NO increased liver cGMP levels while minimally affecting systemic hemodynamics, protecting rats dosed with TNF alpha plus galactosamine from apoptosis and hepatotoxicity and suggest a possible therapeutic strategy for hepatic disorders such as fulminant liver failure.